Brexucabtagene Autoleucel

Introduction Overview

Generic Name

brexucabtagene autoleucel

Brand Name

Tecartus

Dosage Form

suspension for intravenous infusion

Drug Class

Miscellaneous antineoplastics

Pharmacokinetics

Pharmacokinetics of brexucabtagene autoleucel (Tecartus) represent unique characteristics due to its nature as a CAR T-cell therapy, diverging significantly from traditional small-molecule or biologic drugs. The pharmacokinetics involve processes related to the distribution, expansion, persistence, and elimination of genetically modified autologous T-cells after infusion.

Absorption:
Tecartus is administered as an intravenous infusion directly into the bloodstream, bypassing conventional absorption processes. Upon infusion, the CAR T-cells circulate systemically, rapidly encountering and localizing to CD19-expressing cancer cells. There is no reliance on gastrointestinal or subcutaneous absorption; thus, bioavailability is effectively 100% as the cells are delivered directly.

Distribution:
Following infusion, brexucabtagene autoleucel distributes systemically. The CAR T-cells migrate extensively into lymphoid tissues, tumor microenvironments, and peripheral blood. Their distribution is dynamic and can be influenced by tumor burden, presence of target antigen (CD19), and host immune factors. The cells undergo in vivo expansion upon antigen engagement, amplifying their numbers locally and systemically. Distribution is also marked by homing to sites of CD19-positive malignant cells such as lymph nodes, bone marrow, and possibly extranodal sites.

Metabolism:
As a cellular therapy, brexucabtagene autoleucel does not undergo classical metabolic pathways. Instead, the 'metabolism' analog is the proliferation, activation, and eventual apoptosis or exhaustion of the CAR T-cells. Host immune environment and cytokines influence their lifespan and function. Genetically modified T-cells can persist for weeks to months, providing ongoing anti-tumor activity, or may decline due to immune mechanisms or lack of antigen stimulation.

Elimination:
Elimination corresponds to the decline in CAR T-cell population, through natural cell death, immune-mediated clearance, or lack of stimulation in the absence of target antigen. The kinetics of elimination vary according to individual patient response and disease status. There is no renal or hepatic clearance as this is cell-based therapy, but immunologic factors drive the elimination process. Clinically, monitoring of CAR T-cell levels post-infusion correlates with efficacy and toxicity profiles.

Overall, Tecartus pharmacokinetics reflect its function as a living drug, with absorption bypassed, systemic distribution and active expansion in response to antigen, cellular metabolism involving expansion and exhaustion, and elimination through cellular attrition rather than biochemical clearance mechanisms.

Dosage Forms

Available Dosage Forms:
Tecartus is supplied solely as a personalized suspension of brexucabtagene autoleucel cells for intravenous infusion. The product is individualized per patient through genetic modification of their own T-cells.

Specifically, the formulations include:
- For Mantle Cell Lymphoma (MCL): A suspension containing 2 × 10^6 CAR-positive viable T cells per kilogram of body weight, with a maximum dose of 2 × 10^8 CAR-positive viable T cells, in approximately 68 mL volume.
- For B-cell precursor Acute Lymphoblastic Leukemia (ALL): A suspension containing 1 × 10^6 CAR-positive viable T cells per kilogram of body weight, with a maximum dose of 1 × 10^8 CAR-positive viable T cells, also in approximately 68 mL volume.

Dosages for Adults and Adolescents:
Tecartus dosing is individualized based on the patient's weight and cellular product characteristics, with dosing targets as follows:
- For MCL in adults: 2 × 10^6 CAR-positive viable T cells/kg body weight, capped at 2 × 10^8 cells.
- For B-cell precursor ALL in adults: 1 × 10^6 CAR-positive viable T cells/kg body weight, capped at 1 × 10^8 cells.
Dosing in adolescents has not been explicitly established in available data and treatment is typically in adults.

Specific Patient Populations:
As a highly personalized therapy, dosing is carefully tailored. Prior to infusion, lymphodepleting chemotherapy is administered to prepare the patient and optimize CAR T-cell engraftment. Special considerations include avoiding administration during active infections and assessing organ function. Due to potential for severe toxicities, administration occurs only in authorized centers with trained staff capable of managing complications. Pregnant or breastfeeding patients require careful risk-benefit evaluation.

No alternative dosage forms or generic formulations are currently available due to its individualized cell therapy nature.

Mechanism Of Action

Tecartus (brexucabtagene autoleucel) is a chimeric antigen receptor (CAR) T-cell therapy designed to target and eliminate CD19-expressing malignant B-cells. Its mechanism capitalizes on genetic modification of a patient's own T lymphocytes to express CARs that specifically recognize the CD19 antigen, a protein universally expressed on B-lineage lymphocytes in conditions like mantle cell lymphoma and B-cell precursor acute lymphoblastic leukemia.

The process begins with leukapheresis to collect the patient's T-cells, which are then engineered ex vivo to express the CAR construct. This receptor combines an extracellular antigen-recognition domain derived from a monoclonal antibody, linked to intracellular signaling domains that enable T-cell activation and proliferation upon antigen engagement. This design allows the T-cells to identify and bind CD19 on malignant cells independently of classical MHC presentation.

Upon reinfusion, these engineered T-cells circulate and bind specifically to CD19-expressing tumor cells. Binding triggers T-cell activation, proliferation, and release of effector molecules such as perforin and granzymes, inducing apoptosis of targeted malignant cells. Additionally, cytokine production amplifies immune response and recruits other immune effectors.

This targeted approach contrasts with conventional chemotherapy by providing a living drug capable of sustained surveillance and potential curative eradication of cancerous B-cells. Clinical studies demonstrate high overall response rates; however, the potent immune activation underlies risks such as cytokine release syndrome and neurotoxicity, necessitating careful clinical management. Research continues to optimize CAR design and persistence to enhance therapeutic benefit and minimize adverse effects.

Pharmacological Actions

Genetically engineered autologous T-cell immunotherapy targeting CD19 antigen on malignant B-cells.
Specific lysis of CD19-expressing cancer cells via CAR-mediated recognition independent of MHC.
In vivo expansion and persistence of modified T-cells leading to sustained anti-tumor activity.
Induction of apoptosis in tumor cells through release of cytotoxic granules and immune effector functions.
Activation of systemic immune response with associated cytokine production for enhanced tumor eradication.
Lymphodepletion via pre-infusion chemotherapy improves CAR T-cell engraftment and activity.
Potential for durable remission in relapsed or refractory mantle cell lymphoma and B-cell precursor acute lymphoblastic leukemia.
Possibility of off-target effects related to immune activation, including cytokine release syndrome and neurotoxicity.
Risk of secondary malignancies via transformation of genetically modified T-cells.
Differentiated from small-molecule antineoplastics by being a living, personalized cellular therapy.

Therapeutic Or Clinical Uses

Treatment of relapsed or refractory mantle cell lymphoma (MCL) in adults.
Treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults.
Utilized in patients who have not responded to conventional chemotherapy or other standard therapies.
Used as a personalized immunotherapy to induce remission in aggressive B-cell malignancies.
Applied in settings where tumor expresses CD19 antigen, suitable for CAR T-cell targeting.
Option for patients eligible for leukapheresis and authorized centers capable of CAR T-cell delivery.
Used under accelerated approval with ongoing studies to confirm long-term benefit.
Adopted in specialized oncology care centers with infrastructure for monitoring and managing severe toxicities.
Serves as a salvage therapy option in advanced hematologic cancers with poor prognosis.
Potential to reduce tumor burden and improve survival outcomes when other treatments fail.

Side Or Adverse Effects

Cytokine release syndrome (CRS) characterized by fever, hypotension, hypoxia, and multi-organ dysfunction.
Neurologic toxicities including confusion, seizures, aphasia, encephalopathy, and cerebral edema.
Hematologic toxicities such as severe neutropenia, anemia, and thrombocytopenia leading to risk of infections and bleeding.
Low white blood cell counts often accompanied by fever, increasing infection susceptibility.
Hypotension manifesting as dizziness, lightheadedness, and tachycardia.
Nausea, diarrhea, and gastrointestinal discomfort during treatment course.
Allergic reactions including hives, difficulty breathing, and facial or throat swelling.
Kidney impairment presenting as decreased urine output, swelling, and fatigue.
Fluid accumulation in lungs causing respiratory distress, cough with foamy sputum, and wheezing.
Severe ongoing nausea, vomiting, or diarrhea requiring medical intervention.
Possible development of secondary blood cancers due to CAR T-cell transformation.
Fatigue, headache, and general malaise during and after infusion.
Risk of severe drowsiness and impaired cognitive function post-infusion.
Potential for seizures requiring acute management.
Injection site reactions and infusion-related adverse events.

Precautions

Avoid administration in patients with active infections, including fever or flu-like symptoms.
Careful screening of patient history for stroke, seizure, or memory disorders before treatment initiation.
Assessment of liver, kidney, and cardiac function due to risks of organ toxicities.
Pre-treatment evaluation for hepatitis B, hepatitis C, and HIV infections due to risk of reactivation.
Close monitoring for cytokine release syndrome and neurologic toxicities post-infusion.
Pregnancy testing mandatory before treatment due to teratogenic risks; effective contraception advised.
Avoid breastfeeding during and after treatment until safety is established.
Pre-infusion lymphodepleting chemotherapy essential to prepare immune environment.
Continuous monitoring in authorized treatment centers with trained medical teams.
Patients instructed to remain near treatment center for at least two weeks post-infusion.
Do not administer if recent vaccine within 6 weeks owing to potential immunologic interference.
Educate patients on early symptom reporting, including fever, neurologic changes, and bleeding signs.
Delay or withhold treatment if active infections or uncontrolled comorbidities are present.
Do not donate blood, organs, tissues, or cells during and after therapy due to safety concerns.
Post-treatment regular follow-up and laboratory testing mandatory to detect delayed toxicities.

Warnings

Boxed warning for cytokine release syndrome (CRS), a potentially life-threatening inflammatory response.
Serious neurologic toxicities including confusion, seizures, aphasia, and encephalopathy; may be fatal.
Risk of secondary blood cancers arising from malignant transformation of CAR T-cells.
Immediate medical attention required for signs of allergic reactions or severe infusion-related events.
Monitor liver function closely in patients with history of hepatitis due to risk of viral reactivation.
Avoid use in presence of active infection to prevent exacerbation of immune-related complications.
Not recommended during pregnancy because of potential harm to unborn fetus.
Delayed toxicities necessitate prolonged follow-up post-infusion in specialized centers.
Risk of severe cytopenias increasing susceptibility to infections and bleeding episodes.
Patients must have continuous access to emergency medical care following infusion.
Potential for tumor lysis syndrome in patients with high tumor burden upon CAR T-cell activation.
Monitoring required for cardiac and pulmonary adverse effects associated with CRS.
Neurotoxicity may manifest as severe neurocognitive deficits, requiring intensive supportive care.
Avoid concurrent administration of immunosuppressive agents without medical approval.
Discontinue or delay therapy if severe adverse events occur until clinical stabilization.

Contraindication

Active systemic infection or uncontrolled infection at time of planned infusion.
Hypersensitivity to brexucabtagene autoleucel or any excipients such as albumin or DMSO.
Pregnancy and breastfeeding contraindicated due to potential fetal and infant harm.
Patients unable to be monitored in authorized centers with trained personnel.
Severe organ dysfunction limiting the ability to tolerate lymphodepleting chemotherapy or CAR T-cell therapy.
Concurrent participation in other experimental therapies that may interfere with treatment efficacy or safety.
Prior allogeneic stem cell transplantation with active graft-versus-host disease may be a relative contraindication.
Known history of CNS involvement by malignancy with uncontrolled neurologic symptoms.
Severe immunodeficiency states that preclude effective T-cell function.
Hypersensitivity or allergy to components involved in the product manufacturing or infusion process.
Inability to comply with required follow-up and monitoring protocols post-infusion.
Active hepatitis B or C infections not adequately controlled prior to therapy.
Severe cardiovascular instability contraindicating chemotherapy or cellular therapy.
Absence of CD19 expression on malignancy rendering therapy ineffective.
Patients with comorbidities resulting in life expectancy less than required monitoring period.

Drug Interactions

Concomitant immunosuppressants may reduce efficacy and increase risk of infection.
Chemotherapy agents used for lymphodepletion (e.g., fludarabine, cyclophosphamide) necessary for therapy initiation; timing critical for efficacy.
Vaccines administered within 6 weeks before infusion may interfere with immune response.
Medications that alter immune function could exacerbate or mask toxicity symptoms.
Cytokine release syndrome treatment medications (e.g., tocilizumab, corticosteroids) used to manage adverse effects but may influence CAR T-cell persistence.
Other antineoplastic agents administered concurrently require careful scheduling and assessment.
Antibiotics and antifungals should be monitored for potential interactions affecting infection risk management.
Avoid live vaccines during and following therapy due to altered immune status.
Drugs that reduce T-cell function (e.g., calcineurin inhibitors) contraindicated unless medically supervised.
Medications causing QT prolongation may compound cardiac risks associated with CRS.
Concurrent use of sedatives or anticonvulsants may obscure neurologic toxicity signs.
Interactions with herbal or over-the-counter immune modulating supplements have not been established but should be avoided unless approved.
Effectiveness of hormonal contraceptives may be impaired; alternative or additional methods recommended.
No direct drug metabolism interactions due to cellular nature but systemic immunomodulation can alter pharmacodynamics of concomitant drugs.
Patients must report all medications, including vitamins and supplements, to healthcare providers prior to therapy.

Preparations Of The Drug

Tecartus is prepared through leukapheresis to collect patient-derived T-cells from peripheral blood.
Isolated T-cells are genetically modified ex vivo using viral vectors to express a chimeric antigen receptor targeting CD19.
The modified CAR T-cells are expanded and quality-tested in specialized GMP-compliant manufacturing facilities under sterile conditions.
Cell suspensions are formulated in a volume of approximately 68 mL containing viable CAR-positive T-cells tailored to patient weight and disease indication.
Final product is cryopreserved with cryoprotectants such as DMSO and human albumin to maintain cellular viability during transport and storage.
Prior to infusion, cells are thawed and prepared at authorized treatment centers by trained personnel.
The entire manufacturing process from leukapheresis to infusion can span several weeks, requiring close clinical coordination.
Pre-infusion chemotherapy conditioning ('lymphodepletion') is administered to optimize engraftment and activity of infused CAR T-cells.
Product sterility, viability, identity, and functional potency assessments are mandatory release criteria before administration.
No excipients other than human albumin and DMSO are present in the drug formulation.
Due to the personalized nature, no standardized commercial batch; each dose is patient-specific.
Cryopreserved cells are maintained at ultra-low temperatures during shipping in dry ice or vapor phase nitrogen dewars.
Clinical teams receive detailed preparation and administration guidelines from the manufacturer (Kite Pharma, Inc.).
Proper handling protocols to manage infusion reactions and maintain cell viability are strictly followed.
Storage and handling comply with regulatory requirements for advanced cellular therapies.